Pharma Services Stocks Scatter Chart

31 companies Industry group in Healthcare P/E vs Revenue Growth (1y) (TTM)
Universe
Plot any two of 343 metrics The preset pairs are free. Subscribers can put any metric on either axis.
Highlight

P/E vs Revenue Growth (1y) (TTM)

Company Outlier, pinned to the edge Highlighted Trend

Each dot is one of the 31 Pharma Services stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 6.0% and the median P/E 29.94. Pinned to the edge: 3 outliers on X and 2 on Y.

Rank correlation -0.17 Trend R² 0.00 X middle half 1.2% to 11.3% Y middle half 13.20 to 38.74
8High Revenue Growth (1y) (TTM), high P/E
8Low Revenue Growth (1y) (TTM), high P/E
7Low Revenue Growth (1y) (TTM), low P/E
8High Revenue Growth (1y) (TTM), low P/E

Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.

Companies

31 plotted
# Industry
1 TMOThermo Fisher Scientific 8.3% 36.63 $259.44B Life Sciences Tools
2 PFEPfizer 1.3% 40.85 $164.73B Pharmaceuticals
3 TEVATeva Pharmaceutical Industries 2.7% 102.64 $51.97B Generic Drugs
4 IQVIqvia Holdings 8.8% 31.30 $43.67B Contract Research
5 ZTSZoetis 0.9% 13.76 $34.16B Animal Health
6 LHLabcorp Holdings 6.0% 29.94 $30.09B Diagnostic Labs
7 WSTWest Pharmaceutical Services 12.6% 45.92 $29.09B Medical Supplies
8 STESteris 8.1% 31.11 $25.67B Medical Devices
9 IFFInternational Flavors & Fragrances 24.3% 36.61 $20.32B Specialty Chemicals
10 MEDPMedpace Holdings 20.4% 35.28 $18.29B Contract Research
11 CRLCharles River Laboratories International -1.2% 402.10OUT $16.18B Contract Research
12 LDOSLeidos Holdings 2.7% 11.41 $15.93B Defense
13 ICLRIcon 1.8% 34.02 $14.90B Contract Research
14 RDYDr Reddys Laboratories -10.5% 33.78 $12.31B Generic Drugs
15 DVADavita 6.4% 12.11 $11.06B Healthcare Services
16 PODDInsulet 26.5% 24.66 $10.58B Medical Devices
17 LNTHLantheus Holdings 2.4% 24.58 $6.64B Diagnostic Equipment
18 CAICaris Life Sciences 61.5%OUT 68.09 $6.61B Diagnostic Labs
19 LGNDLigand Pharmaceuticals 1.0% 119.78OUT $6.18B Biotechnology
20 OGNOrganon -3.2% 17.14 $3.65B Pharmaceuticals
21 ADMAAdma Biologics 6.3% 16.78 $3.05B Biotechnology
22 AMPHAmphastar Pharmaceuticals 3.1% 12.64 $1.25B Generic Drugs
23 IARTIntegra Lifesciences Holdings 0.8% 85.64 $1.12B Medical Devices
24 MGTXMeiraGTx Holdings 1,366%OUT 11.36 $896.15M Gene and Cell Therapy
25 EMBCEmbecta -7.6% 4.32 $366.02M Medical Devices
26 WDHWaterdrop 76.3%OUT 6.31 $360.88M Insurance Brokers
27 ELTPElite Pharmaceuticals 17.8% 5.90 $355.46M Generic Drugs
28 UTMDUtah Medical Products -9.6% 22.09 $228.50M Medical Devices
29 NSYSNortech Systems 9.0% 16.97 $30.89M Industrial Machinery
30 PLURPluri 10.0% 0.00 $15.09M Gene and Cell Therapy
31 PBSVPharma-Bio Serv 3.3% 45.53 $11.45M Consulting

Frequently Asked Questions

Which Pharma Services stocks look cheap relative to their growth?

Among Pharma Services stocks, the largest companies growing revenue faster than the median (6.0%) while trading below the median P/E (29.94) are Davita (DVA), Insulet (PODD), Adma Biologics (ADMA), MeiraGTx Holdings (MGTX) and Waterdrop (WDH). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.

Which Pharma Services stocks are expensive for their growth?

The largest companies with a P/E above the median and revenue growth below it are Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Charles River Laboratories International (CRL), Icon (ICLR) and Dr Reddys Laboratories (RDY).

What is the median P/E of Pharma Services stocks?

The median P/E across the 31 Pharma Services stocks plotted is 29.94, with the middle half between 13.20 and 38.74.

What is the median Revenue Growth (1y) (TTM) of Pharma Services stocks?

The median is 6.0%, with the middle half between 1.2% and 11.3%.

Is there a relationship between Revenue Growth (1y) (TTM) and P/E for Pharma Services stocks?

The rank correlation (Spearman) is -0.17, a weak negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.

How does this chart handle outliers?

A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 3 companies are outliers on Revenue Growth (1y) (TTM) and 2 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.

Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry group is included unless you choose primary industry only. Nothing on this page is investment advice.